Market closed

Kymera Therapeutic/$KYMR

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Kymera Therapeutic

Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients.

Ticker

$KYMR
Sector
Health Care
Trading on
NASDAQ

Industry

Biotechnology
Headquarters
Watertown, United States

Employees

184
Website
www.kymeratx.com

KYMR Metrics

BasicAdvanced
$2.4B
-
-$2.41
2.22
-

$2.4B

2.22

$51.84

$26.34

454K

8.548

8.286

8.442

9.881

-806.89%

-15.38%

-26.00%

29.597

2.7

2.7

-17.487

86.92%

-16.38%

7.57%

12.14%

What the Analysts think about KYMR

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Kymera Therapeutic stock.

KYMR Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

KYMR Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

KYMR News

AllArticlesVideos
Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs

Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs

GlobeNewsWire·1 day ago
Kymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14

Kymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14

GlobeNewsWire·1 week ago
Kymera: Protein Degradation Could Drive Dupixent-Like Value

Kymera: Protein Degradation Could Drive Dupixent-Like Value

Seeking Alpha·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $KYMR

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Kymera Therapeutic stock?

Kymera Therapeutic (KYMR) has a market cap of $2.4B as of January 15, 2025.

What is the P/E ratio for Kymera Therapeutic stock?

The price to earnings (P/E) ratio for Kymera Therapeutic (KYMR) stock is 0 as of January 15, 2025.

Does Kymera Therapeutic stock pay dividends?

No, Kymera Therapeutic (KYMR) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Kymera Therapeutic dividend payment date?

Kymera Therapeutic (KYMR) stock does not pay dividends to its shareholders.

What is the beta indicator for Kymera Therapeutic?

Kymera Therapeutic (KYMR) has a beta rating of 2.22. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.